![](https://aspirawh.com/wp-content/uploads/2022/10/Ova1Plus-Logo-OvaWatch.png)
Part of the OvaSuiteSM portfolio of blood tests, Ova1Plus® is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
![](https://aspirawh.com/wp-content/uploads/2022/11/index-collage-08-edited.jpg)
Ova1® is performed first, leveraging its high sensitivity1. Overa®, with its high specificity2, is automatically performed when an intermediate risk is detected.
![](https://aspirawh.com/wp-content/uploads/2022/10/0905-reflex-graphic-1024x338.png)
Low Risk is <4.4 (Postmenopausal) and <5.0 (Premenopausal) Intermediate Risk is 4.4-6.0 (Postmenopausal) and 5.0-7.0 (Premenopausal) Markedly Elevated Risk is >6.0 (Postmenopausal) and >7.0 (Premenopausal)
![](https://aspirawh.com/wp-content/uploads/2022/10/0905-Infographic-–-1-1024x226.png)
Learn more about Ova1’s high performance compared to CA 125 alone!
With 4 additional biomarkers and a proprietary algorithm, Ova1 has dramatically improved performance compared to CA 125 alone.
![](https://aspirawh.com/wp-content/uploads/2022/11/0905_59_-circle-chart-1024x478.png)
Ova1 demonstrates improved performance across certain ethnicities, compared to CA 125 alone.4
![](https://aspirawh.com/wp-content/uploads/2022/10/0905_sensitivity-bar-chart-1024x347.png)
Biomarkers in Ova1 & Overa
![](https://aspirawh.com/wp-content/uploads/2022/10/ova1-1024x348.png)
![](https://aspirawh.com/wp-content/uploads/2022/10/overa-1024x348.png)
Arrows indicate the typical trends of biomarkers in the case of an Elevated Risk result.
Not planning for surgery?
![ovawatch](https://aspirawh.com/wp-content/uploads/2022/09/Aspira_OVAWatchSM-logo_RGB-1024x234.png)
Utilize the OvaSuite portfolio of products and confidently move from assessment to action.
A single blood draw – which can be performed at a number of national and regional laboratories or in a healthcare provider's offices using our proprietary testing kit – is all that is needed.
Contact us to learn more, order kits, or to locate one of our phlebotomy partners.
- Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic oncology, 128(2), 252-259.
- Dunton, C. J., Bullock, R. G., Fritsche, H. A., & Twiggs, L. B. (2020). Improvement in MIA (OVA1) testing for detection of ovarian malignancy. Gynecologic Oncology, 159, 25.
- Dunton, C. J., Hutchcraft, M. L., Bullock, R. G., Northrop, L. E., & Ueland, F. R. (2021). Salvaging detection of early-stage ovarian malignancies when ca125 is not informative. Diagnostics, 11(8), 1440.
- Dunton, C., Bullock, R. G., & Fritsche, H. (2019). Ethnic disparity in clinical performance between multivariate index assay and CA125 in detection of ovarian malignancy. Future Oncology, 15(26), 3047-3051.